Healthcare news summaries — Page 2
Essential facts and source links for recent healthcare stories.
-
Guggenheim lifts Foundayo revenue outlook as prescriptions grow
Guggenheim raised 2027 and 2028 revenue forecasts for Eli Lilly’s oral obesity drug Foundayo to $1.8 billion and $3.7 billion, from $1.2 billion and $2.4 billion, respectively, as prescriptions improved. Its 2026 estimate was unchanged despite a lower modeled 2.5-mg price. -
Medicare costs could consume up to a third of Social Security’s 2027 raise
Social Security’s 2027 raise is forecast at 3.5%–3.6%, but Madison Partners estimates Medicare costs could absorb one-fifth to one-third of a 3.5% increase. The SSA will announce the COLA Oct. 14; at 3.5%, the average retired worker would get about $72 more monthly. -
Eli Lilly stops GLP-1 weight-loss candidate after efficacy falls short
Eli Lilly halted development of an unnamed GLP-1 weight-loss drug candidate after it fell short of the company’s efficacy expectations. In the second quarter of 2026, Mounjaro, Zepbound and its new pill Foundayo together accounted for just over 65% of revenue. -
Needham starts GE HealthCare coverage with a Buy rating; $93 target implies 44% upside
Needham initiated GE HealthCare coverage with a Buy rating and a $93 target, implying about 44% upside from the stock’s Sept. 21 close of $64.81. Analyst David Saxon said shares reflected a bear-case outlook after falling about 20% since January. -
Workers over 40 advised to document age-related remarks at work
U.S. employment lawyers advise workers 40 and older facing age-related remarks to save messages and note what was said, when and who heard it, then report concerns in writing to HR or a supervisor. Comments alone may not support a legal claim without a pattern of treatment or an. -
ER clinicians say aggression can disrupt care for others
ER clinicians urge patients and visitors not to yell at or assault staff. Emergency rooms prioritize by medical urgency, and aggression can disrupt care for others; one cited study found 66% of ER physicians reported being assaulted in the past year. -
U.S. health insurance premiums rose 78% in 13 years as some workers dropped coverage
U.S. average annual health insurance premiums rose from $4,008 in 2011 to $7,151 in 2024, up 78.4%—twice the overall inflation rate, a JAMA study found. Some healthcare workers are uninsured; Boise doctor Joshua Durham and pharmacist Ashley Durham canceled coverage this year. -
Commonwealth Fund survey finds 32% of insured working-age adults repaying medical debt
A Commonwealth Fund survey found 32% of working-age U.S. adults with health insurance are paying off medical debt; 46% of them owe at least $2,000. The debt caused anxiety and stress for 68% of respondents; some cut back on food, heat or rent or skipped future care. -
AARP projects a 3.6% Social Security COLA for 2027, but premiums may trim gains
AARP estimates Social Security’s 2027 cost-of-living adjustment at 3.6%, but Medicare Part B premiums may erode it. The monthly premium is projected to rise from $202.90 in 2026 to $218.60 in 2027, so a $50 monthly benefit increase would net $34.30 after premiums. -
Fort Worth parents sue daycare for $1 million over alleged assault on 4-year-old
Parents Heather and Richard Harris are suing Fort Worth’s Arka Montessori Academy for $1 million, alleging a substitute encouraged a fight, grabbed and shoved a 4-year-old, then stood aside as her son attacked him; another teacher allegedly did not intervene. -
Doctor invested in Healz AI after it suggested a second opinion for his wife
Atlanta psychiatrist Munjal Shroff says Healz AI encouraged a second opinion at MD Anderson, where his wife was diagnosed with rare T-cell lymphoma after months of unexplained symptoms. He kept using the chatbot through her treatment and later invested in the startup. -
Lilly’s growth outlook is stronger, but its GLP-1 lead may not last
Since mid-2024, Eli Lilly shares have gained about 35%, while Novo Nordisk’s have fallen roughly 74%. Lilly trades at about 24.4 times forward earnings versus 11.8 for Novo; the article sees Lilly’s growth outlook as stronger but says its GLP-1 edge may not endure. -
ABIVAX projects runway into Q4 2029 after cash use rises 54%
ABIVAX reported first-half 2026 operating cash use of €102.5 million, up from €66.6 million a year earlier. July's equity financing added €767.1 million net; the company projects its resources will fund operations into Q4 2029 under current assumptions. -
Alkermes reports early ADHD score declines for ALKS 7290; placebo benefit unknown
Alkermes reported median ADHD symptom-score declines of 14 points at 20 mg per day and 19 at 50 mg per day after 14 days of split-dose ALKS 7290 in a 50-person adult trial. The Phase 1b study included placebo but did not establish benefit over it. -
CUE-221 trial finds full hive resolution in 54% on highest dose
Cue Biopharma said its Phase 2 trial in China found complete resolution of chronic hives at week 12 in 54% of patients given CUE-221 at 4 mg/kg, versus 11% on placebo. The 145-patient study met its primary endpoint; its week-28 omalizumab comparison was post hoc. -
Eurocontrol freezes Polish, Romanian air-fee transfers as Pfizer enforces €1.9bn judgment
Pfizer is enforcing a Belgian judgment requiring Poland and Romania to pay €1.9 billion for vaccine doses they declined under a 2021 EU contract. Eurocontrol has frozen route-fee transfers to their aviation agencies as both countries challenge enforcement. -
Roughly half of New York home care is under private-equity control
Cornell’s Worker Institute says private equity controls roughly half of New York’s home-care market, now consolidated and highly leveraged. PE-backed agencies collected more than $2.32 billion in Medicaid payments in 2022; debt service takes funds from care and wages. -
Apple plans iOS 27 Health revamp with readiness scores and Watch sensors
Apple plans an iOS 27 Health app redesign with Apple Intelligence guidance and a daily 0–10 readiness score combining activity, sleep and vital signs, the Wall Street Journal reported. The report also links it to upgraded sensors in Apple Watch Series 12 and Ultra 4. -
After three deaths, Novartis pauses eight CAR-T trials; Bristol Myers pauses new enrollment
Novartis paused eight autoimmune and neurological rap-cel CAR-T trials after three patients died from a rare, severe immune reaction. Bristol Myers paused new enrollment in zola-cel trials after events it called transient and reversible; it reported no deaths. -
Novartis investor seeks board shake-up over acquisition oversight
Artisan Partners, one of Novartis’ 20 largest shareholders, called for a board shake-up to improve acquisition oversight after two trial failures preceded an 11% one-day drop, erasing nearly $30 billion in market value and the stock’s 2026 gains. -
Motley Fool sees more upside in AbbVie than J&J for 2026
The Motley Fool sees greater upside in AbbVie, citing its 18.8x forward P/E and pipeline, compared with Johnson & Johnson’s 23.5x. J&J posted the higher FY2025 net margin; AbbVie faces patent and revenue-concentration risks, while J&J faces talc litigation. -
Elysium launches TELI as a telehealth program for longevity care
Elysium Health launched TELI Sept. 9, an online longevity-care program where licensed providers assess eligible adults and create personalized plans when clinically appropriate. Its 18 protocols cover prescription drugs, peptides, supplements and vitamins. -
Gias Foods recalls two lots of Walmart’s bettergoods fettuccine over possible Listeria
Gias Foods recalled two lots of Walmart’s bettergoods Authentic Italian Lemon Alfredo Fettuccine after state testing indicated they may contain Listeria. The bags were sold nationwide, and the company says no illnesses have been reported to date. -
Alice Walton’s net worth rose $33 billion; her medical school has 96 students
Alice Walton’s net worth rose $33 billion from March 2025 to March 2026, according to Forbes data cited by Fortune. Her Arkansas medical school has 96 students and waives tuition for its first five graduating classes; students pay fees and living costs. -
Buffalo fund says confidence in Corcept's execution and pipeline aided shares
In its Q2 2026 letter, Buffalo Mid Cap Discovery Fund said Corcept Therapeutics added to its relative performance, with the stock benefiting from improved investor confidence in the company’s commercial execution and pipeline opportunities. -
Pennsylvania Reddit example illustrates income’s role in pre-65 insurance costs
A Pennsylvania Reddit commenter cited 2026 estimates for a married couple’s cheapest ACA Silver plan: $3,672 at $35,000 MAGI, $4,908 at $45,000 and $30,660 at $100,000. The example illustrates how income can affect coverage costs before Medicare eligibility at 65. -
Ashland’s Permexa launch comes amid Life Sciences growth and wider EBITDA decline
Ashland launched Permexa sodium caprate on Aug. 24 to help drugmakers make oral versions of injectable peptides and biologics; no product revenue figure has been disclosed. Q3 Life Sciences sales rose 11% to $180 million, while companywide adjusted EBITDA fell 4% to $109 million.
